Recombinant Human CD300a/LMIR1 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD300a/LMIR1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED₅₀ for this effect is 1-5 µg/mL.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Mouse myeloma cell line, NS0-derived human CD300a/LMIR1 protein
  

  Human CD300a (Leu18-Gln178) Accession # Q9UGN4	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q9UGN4
• N-terminal Sequence: Leu18
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CD300A
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 44.0 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-80 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD300a/LMIR1 Fc Chimera Protein, CF

• CD300a antigenCMRF35H9
• CD300a molecule
• CD300a
• CLM8
• CLM-8
• CMRF35H leukocyte immunoglobulin-like receptor
• CMRF-35H
• CMRF35-H
• CMRF35-H9
• CMRF-35-H9CD300 antigen-like family member A
• CMRF35HIRp60
• CMRF35-like molecule 8
• IGSF12
• IGSF12NK inhibitory receptor
• Immunoglobulin superfamily member 12
• Inhibitory receptor protein 60
• IRC1
• IRC1/IRC2
• IRC2
• IRp60
• leukocyte membrane antigen
• LMIR1
• MAIR-I
• Mcipr1
• NKRL
• Pigr4

Background

LMIR1, also known as CD300a, CMRF-35H, IRp60, CLM-8, and MAIR-I, is a 60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human LMIR1 consists of a 163 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 98 aa cytoplasmic domain that contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-canonical ITIM (2). Alternate splicing may generate additional isoforms that either lack the Ig-like domain or contain only the cytoplasmic domain. Within the ECD, human LMIR1 shares 40% and 43% aa sequence identity with mouse and rat LMIR1, respectively. In human, LMIR1 is expressed on peripheral blood eosinophils, mast cells, neutrophils, plasmacytoid dendritic cells, and various T cell subsets (3-7). Antibody cross‑linking of LMIR1 induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5-7). Cross‑linking of LMIR1 to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (5, 10‑12). LMIR1
cross‑linking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 11, 12).

1. Clark, G.J. et al. (2009) Trends Immunol. 30:209.
2. Cantoni, C. et al. (1999) Eur. J. Immunol. 29:3148.
3. Munitz, A. et al. (2006) Blood 107:1996.
4. Bachelet, I. et al. (2005) J. Immunol. 175:7989.
5. Alvarez, Y. et al. (2008) Mol. Immunol. 45:253.
6. Ju, X. et al. (2008) Blood 112:1184.
7. Clark, G.J. et al. (2007) J. Leukoc. Biol. 82:1126.
8. Kumagai, H. et al. (2003) Biochem. Biophys. Res. Commun. 307:719.
9. Yotsumoto, K. et al. (2003) J. Exp. Med. 198:223.
10. Bachelet, I. et al. (2008) J. Immunol. 180:6064.
11. Bachelet, I. et al. (2006) J. Allergy Clin. Immunol. 117:1314.
12. Munitz, A. et al. (2006) J. Allergy Clin. Immunol. 118:1082.

Bioinformatics

• Gene Symbol: CD300A
• Uniprot:
  • Q9UGN4()